Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.35 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.35 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.35 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.35 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28294101 | 0.79 | NR4A2 (0.41) | HPGDSMN1; SMN2TSHRHTTL3MBTL1 | |
| SCHEMBL7575058 | 0.79 | PLK1 (0.49) | HPGDSMN1; SMN2TSHRHTTPLK1 | |
| SCHEMBL7584988 | 0.79 | MAOB (0.38) | HPGDTSHRHTT | |
| SCHEMBL10388530 | 0.78 | ALOX15 (0.41) | HDAC8HDAC6HDAC2HPGDSMN1; SMN2 | |
| SCHEMBL3991217 | 0.78 | GAA (0.39) | HDAC8HDAC6HDAC2HPGDSMN1; SMN2 | |
| SCHEMBL10388842 | 0.77 | NPC1 (0.49) | SMN1; SMN2TSHRHTTLMNA | |
| SCHEMBL4023724 | 0.76 | KDM4E (0.39) | HPGDSMN1; SMN2RXFP1SORT1 | |
| SCHEMBL10388490 | 0.76 | PARP1 (0.45) | HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL28079948 | 0.74 | GAA (0.41) | HPGDSMN1; SMN2RXFP1L3MBTL1LMNA | |
| SCHEMBL7574364 | 0.74 | ALDH1A1 (0.46) | HPGDSMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| US-8207340-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-06-26 | — | — | US | disclosed |
| US-7795448-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | disclosed |
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INCORPORATED | 2006-05-04 | — | — | US | disclosed |
| US-4971957-A | ANTILIPEMIC AGENTS, ANTICHOLESTEROL AGENTS, BENZENECARBOXAMIDOPHOSPHONATES OR BENZENETHIOCARBOXAMIDOPHOSPHONATES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1990-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | KIF5B, KIF18A, KIF2C | CREBBP 447/4885HDAC8 15/4885HDAC6 70/4885 |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CREBBP 1718/4885HDAC8 390/4885HDAC6 137/4885 |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CREBBP 1718/4885HDAC8 390/4885HDAC6 137/4885 |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | CREBBP 1718/4885HDAC8 390/4885HDAC6 137/4885 |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | CREBBP 1515/4885HDAC8 357/4885HDAC6 160/4885 |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CREBBP 1718/4885HDAC8 390/4885HDAC6 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.